Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL)Oliver G. Ottmann(Goethe University Frankfurt)BloodApril 4, 200710.1182/blood-2006-11-052373Cited by 249SaveCiteExport RISWatch citationsRelated PapersDifferential Effects of Selective Inhibitors Targeting the PI3K/AKT/mTOR Pathway in Acute Lymphoblastic Leukemia|PLoS ONE|2013|70